Start with the protein site. Design the molecule. Test the function.

A design-first approach to protein biology
Proteins act through specific surfaces, motifs and interactions. Nemdx uses the target protein sequence and a selected site to design complementary oligonucleotide binders intended to engage that region directly.

Designed rather than screened
Conventional discovery often starts with large libraries and searches for candidates that bind. Nemdx reverses the process: choose the biologically relevant site first, design the molecule to that site, then test whether it performs the intended function.

Designed for therapeutic function
The same design logic can be directed toward selected protein-protein interfaces or configured to support intracellular delivery. Nemdx has demonstrated both PPI inhibition and cell penetration in vitro.

Validated through human measurement
The platform has also generated a TDP-43 functional activity assay evaluated across 1,080 human samples and published in Biosensors in 2026. That human biomarker work provides validation that sequence-designed molecules can recognize functionally relevant protein biology in blood.

Partner on a therapeutic target
CTA: Discuss a target